Compile Data Set for Download or QSAR
Report error Found 273 Enz. Inhib. hit(s) with all data for entry = 10709
TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404387((R)-N-(1-cyanopyrrolidin-3-yl)-3- methoxy-4-(2-met...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM560978(US11390584, Example 38 | (R)-4-(3-chloropyridin-4-...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404386((R)-4-(3-chloropyridin-4-yl)-N- (1-cyanopyrrolidin...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404515((R)-6-(3-cyanophenyl)-N-(1-cyanopyrrolidin-3-yl)-3...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404392((R)-N-(1-cyanopyrrolidin-3-yl)-4- (1-methyl-1H-pyr...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404520((R)-N-(1-cyanopyrrolidin-3-yl)-2-fluoro-4-(pyrazol...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404521((R)-N-(1-cyanopyrrolidin-3-yl)-5-(4-fluorophenyl)p...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404523(3-chloro-N-((trans)-1-cyano-4-methylpyrrolidin-3-y...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404529((R)-N-(1-cyanopyrrolidin-3-yl)-4-(2, 6-dimethylpyr...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM504675(rac-(3aR,6aR)-1-([1,1'-biphenyl]- 3-carbonyl)hexah...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404505((R)-N-(1-cyanopyrrolidin-3-yl)-N-methyl-5-(1-methy...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404502((R)-N-(1-cyanopyrrolidin-3-yl)-6-(3, 5-dimethyliso...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404503((R)-N-(1-cyanopyrrolidin-3-yl)-1-(cyclopropylmethy...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404508((R)-7-(3-cyanophenyl)-N-(1-cyanopyrrolidin-3-yl)im...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404383((R)-6-(4-chlorophenyl)-N-(1- cyanopyrrolidin-3-yl)...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404384((R)-2-(2-chlorophenyl)-N-(1- cyanopyrrolidin-3-yl)...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404382((R)-N-(1-cyanopyrrolidin-3-yl)- [1,1'-biphenyl]-4-...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404420(US10343992, Example 72 | US10689345, Example 72 | ...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM447662((3aR,6aR)-5-cyano-N-(2- fluoro-5-(trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404418(US10343992, Example 70 | US10689345, Example 70 | ...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404424((R)-N-(1-cyanopyrrolidin-3-yl)-3- fluoro-4-(1-meth...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404552((R)-1-(1-cyanopyrrolidin-3-yl)-1-ethyl-3-(4-(trifl...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404425((R)-N-(1-cyanopyrrolidin-3-yl)-2- fluoro-4-(1-meth...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM505530((3aR,6aR)-5-cyano-N-(5- phenyl-pyridin-2-yl) hexah...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM505531((3aR,6aR)-5-cyano-N-(4- (trifluoromethyl)-phenyl)-...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404428((R)-N-(1-cyanopyrrolidin-3-yl)-4- (1,3-dimethyl-1H...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404429((R)-N-(1-cyanopyrrolidin-3-yl)-4- (1-ethyl-1H-pyra...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404426((R)-N-(1-cyanopyrrolidin-3-yl)- 2,5-difluoro-4-(1-...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404427((R)-N-(1-cyanopyrrolidin-3-yl)-4- (1,3-dimethyl-1H...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404560((R)-N-(1-cyanopyrrolidin-3-yl)-4-(4-cyclopropylpyr...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404433((R)-N-(1-cyanopyrrolidin-3-yl)-2- fluoro-4-(5-(tri...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404561((R)-N-(1-cyanopyrrolidin-3-yl)-4-((4-cyclopropylpy...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM561124(US11390584, Example 184 | (R)-N-(1- cyanopyrrolidi...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404533((R)-N-(1- cyanopyrrolidin- 3-yl)-2-fluoro-4- (imid...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404530((R)-N-(1- cyanopyrrolidin- 3-yl)-2-fluoro-4- (5-fl...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404540((R)-3-(3-chlorophenyl)-N-(1-cyanopyrrolidin-3-yl)a...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404538((R)-N-(1-cyanopyrrolidin-3-yl)-3-(4-methoxyphenyl)...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404539((R)-3-(4-chlorophenyl)-N-(1-cyanopyrrolidin-3-yl)a...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM447658((3aR,6aR)-5-cyano-N-(2- fluoro-4-(trifluoromethoxy...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404580((R)-N-(1-cyanopyrrolidin-3-yl)-3-fluoro-1-methyl-5...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404453((R)-N-(1-cyanopyrrolidin- 3-yl)-2-fluoro-4-(2- met...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM505430((R)-N-(1- cyanopyrrolidin- 3-yl)-5-phenyl- 1H-pyra...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM505558((R)-N-(1-cyanopyrrolidin-3-yl)-1-methyl-5-(1-methy...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404585((R)-3-(2-(4-chlorophenyl)pyrimidin-4-yl)-N-(1-cyan...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404582((R)-N-(1-cyanopyrrolidin-3-yl)-3-(1-phenyl-1H-pyra...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404460((R)-N-(1-cyanopyrrolidin- 3-yl)-3,5-difluoro-4-(1-...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404588((R)-N-(1-cyanopyrrolidin-3-yl)-1-(4-cyclopropylpyr...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404589((3aR,6aR)-5-cyano-N-(3-(2-methylpyridin-4-yl)pheny...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404586((R)-3-(benzyloxy)-N-(1-cyanopyrrolidin-3-yl)-3-phe...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404587((R)-N-(1-cyanopyrrolidin-3-yl)-1-(4-cyclopropylpyr...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
US Patent

Displayed 1 to 50 (of 273 total ) | Next | Last >>
Jump to: